A. Because of the wide availability of vaccines, pneumonia is no longer a leading cause of death in the United States B. Patients with hypertension are at an increased risk of pneumococcal pneumonia and complications C. Streptococcus pneumoniae is the leading bacterial cause of community acquired pneumonia D. Once patients reach the age of 50, they are at an increased risk of complications from pneumococcal disease E. Unsure

A. Pneumococcal conjugate vaccine 13 (PCV13) B. PCV15 C. PCV20 D. Pneumococcal polysaccharide vaccine (PPSV23) E. Unsure

A. PCV13 B. PCV15 C. PCV20 D. PPSV23 E. Unsure

A. 1 dose of PCV15 alone B. 1 dose of PCV20 alone C. 1 dose of PCV20 + 1 dose of PPSV23 D. Pneumococcal vaccination is not recommended since the patient has no chronic conditions E. Unsure

A. No, the patient does not need further pneumococcal vaccination B. No, the patient should receive 1 dose of either PCV15 or PCV20 instead C. Yes, the patient should receive a second PPSV23 dose since it has been more than 5 years since his last PPSV23 dose D. Yes, but the patient should receive 1 dose of either PCV15 or PCV20 first, then PPSV23 at least 1 year later E. Unsure

A. No vaccination necessary until age 65, then 1 dose of PCV20 alone or 1 dose of PCV15 + 1 dose of PPSV23 1 year later B. No vaccination necessary until age 65, then 1 dose of PCV20 alone or 1 dose of PCV15 + 1 dose of PPSV23 8 weeks later C. One dose of PCV20 alone or 1 dose of PCV15 + 1 dose of PPSV23 1 year later with no further pneumococcal vaccination D. One dose of PCV20 alone or 1 dose of PCV15 + 1 dose of PPSV23 1 year later; repeat this series at the age of 65 E. Unsure

A. A single dose of PPSV23 today, since it has been at least 8 weeks since PCV13 B. A single dose of PPSV23 at least 5 years after the previous PCV13 dose C. A single dose of PCV20 alone or a single dose of PCV15 followed by PPSV23 8 weeks later D. Two doses of PPSV23—1 today and 1 at least 5 years after the last dose of PPSV23 E. Unsure

A. Complacency B. Confidence C. Context D. Convenience E. Unsure

A. Only PCV13 and PCV15 may be coadministered safely with the influenza vaccine B. There are no safety or efficacy data available regarding coadministration of PCV15 or PCV20 with the Tdap or zoster vaccines C. Data suggest PPSV23 may be coadministered safely with the zoster vaccine, but the Centers for Disease Control and Prevention (CDC) recommends against coadministration D. Data support safety and efficacy of coadministration of PCV and PPSV23 at the same visit E. Unsure

A. Vaccine hesitancy has decreased at the onset of the COVID-19 pandemic B. Vaccine hesitancy was a threat to global health before the start of the COVID-19 pandemic C. The COVID-19 pandemic increased complacency, which worsened vaccine hesitancy D. Vaccine hesitancy occurs for a number of reasons and affects all ethnicities and races equally E. Unsure